David H. Henry, MD, on Advances in Lung Cancer, Colorectal Cancer: Expert Perspective
2017 ASCO Annual MeetingDavid H. Henry, MD, of Pennsylvania Oncology Hematology Associates, outlines abstracts focusing on chemotherapy in locally advanced rectal cancer and immune-related toxicity, response to anti–PD-L1 blockade, and epacadostat plus pembrolizumab in lung cancer.
Related Videos
Lisa A. Carey, MD, and Richard S. Finn, MD, on Breast Cancer: Findings From the PALOMA-1/TRIO 18 Trial
Lisa A. Carey, MD, of the University of North Carolina, and Richard S. Finn, MD, of UCLA Medical Center, discuss phase II overall survival findings on palbociclib in combination wi...
Karim Fizazi, MD, PhD, on Prostate Cancer: Results From the LATITUDE Trial
Karim Fizazi, MD, PhD, of the University Paris-Sud, discusses study findings on androgen-deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed...
Neeraj Agarwal, MD, and Sumanta K. Pal, MD, on Prostate Cancer: Expert Perspectives on the LATITUDE Trial
Neeraj Agarwal, MD, of Huntsman Cancer Institute, and Sumanta K. Pal, MD, of the City of Hope, examine the study findings on androgen-deprivation therapy with abir...
Ethan M. Basch, MD, on Symptom Monitoring: Findings on Overall Survival Rates
Ethan M. Basch, MD, of the University of North Carolina, discusses results from a study that assessed patient-reported outcomes for symptom monitoring during routine cancer treatme...
David I. Quinn, MBBS, PhD, on Urothelial Cancer: Results from KEYNOTE-045
David I. Quinn, MBBS, PhD, of the University of Southern California, gives his expert perspective on the planned survival analysis from a phase III open-label study of pembrolizuma...
